# US 2015/0104866 A1 · Ip-10 antibodies and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104866 A1
- Document ID: US20150104866A1
- Status: Published application
- Kind: A1
- Application number: 14/579,156
- Filed: 2014-12-22
- Published: 2015-04-16
- Earliest claimed: 2003-12-10
- Assignees: Medarex, Inc.
- Applicants: Medarex, L.L.C.
- Inventors: Shrikant DESHPANDE; Haichun HUANG; Mohan SRINIVASAN; Josephine M. CARDARELLI; Changyu WANG; David B. PASSMORE; Vangipuram RANGAN; Thomas E. LANE; Hans S. KEIRSTEAD; Michael T. LIU
- Web page: https://patentgrep.com/patent/US20150104866A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/16: Central respiratory analeptics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/522: {Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

## Claims

### Claim 1

An isolated nucleic acid molecule which encodes a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 39, or a sequence which is at least 80% identical to SEQ ID NO: 39, and/or which encodes a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 88, or a sequence which is at least 80% identical to SEQ ID NO: 88, wherein the variable region binds human IP-10 (SEQ ID NO: 121).

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1, encoding a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 5, 17, and 28, respectively, and/or a light chain variable region comprising CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 55, 66, and 77, respectively.

### Claim 3 (depends on 1)

The nucleic acid molecule of claim 1, wherein the heavy and light chain variable regions comprise the amino acid sequence set forth in SEQ ID NO: 39 and SEQ ID NO: 88, respectively.

### Claim 4

An isolated nucleic acid molecule which encodes a heavy and/or light chain variable region which binds an epitope on human IP-10 (SEQ ID NO: 121) recognized by an antibody comprising a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 39 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 88.

### Claim 5

An isolated nucleic acid molecule which encodes a heavy chain variable region comprising the nucleotide sequence set forth in SEQ ID NO: 103, or a sequence which is at least 80% identical to SEQ ID NO: 103, and/or which encodes a light chain variable region comprising the nucleotide sequence set forth in SEQ ID NO: 114, or a sequence which is at least 80% identical to SEQ ID NO: 114, wherein the variable region binds human IP-10 (SEQ ID NO: 121).

### Claim 6 (depends on 5)

The nucleic acid molecule of claim 5, encoding a heavy chain variable region comprising the nucleotide sequence set forth in SEQ ID NO: 103, and/or a light chain variable region comprising the nucleotide sequence set forth in SEQ ID NO: 114.

### Claim 7 (depends on 1, 4, 5)

The nucleic acid molecule of any one of claim 1, 4 or 5, wherein the heavy and light chain variable regions exhibit at least one of the following functional properties:
(i) cross-reacts with rhesus monkey IP-10 (SEQ ID NO: 123);
(ii) does not cross-react with mouse IP-10 (SEQ ID NO: 124);
(iii) does not cross-react with human MIG (SEQ ID NO: 125); or
(iv) does not cross-react with human ITAC (SEQ ID NO: 126).

### Claim 8 (depends on 1, 4, 5)

An expression vector comprising the nucleic acid molecule of any one of claim 1, 4 or 5.

### Claim 9 (depends on 8)

A host cell comprising the expression vector of claim 8.
